[Results of treatment with interferon and vinblastine in renal cancer].
Contribution of our experience with Alpha-2a Interferon and Vinblastine, for the treatment of advanced renal cancer in patients formerly not treated with nephrectomy. Pathoanatomical diagnosis was confirmed by puncture biopsy. None of the 4 patients recruited in the protocol showed objective response. In 2 patients no change was observed and in the other 2 the disease progressed. In surviving patients it was impossible to sustain therapy for more than three months. Treatment was discontinued as a result of the Interferon side-effects, such as fever, myalgia, asthenia and neuritis.
Ojea Calvo
A
A
Servicio de Urología, Hospital Xeral de Vigo.
Castro Iglesias
A M
AM
Rodríguez Iglesias
B
B
Benavente
J
J
Barros
J M
JM
Figueiredo
L
L
Eceolaza
J
J
Nogueira March
J L
JL
D001707:Biopsy, Needle; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D009367:Neoplasm Staging; D011994:Recombinant Proteins; D015996:Survival Rate; D014057:Tomography, X-Ray Computed; D014747:Vinblastine / Q000627:therapeutic use*
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D014747:Vinblastine
Resultados del tratamiento con interferón y vinblastina en el cáncer de riñón.